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Abstract
Background: Bronchoscopy plays a key role to diagnose the etiology, to localize the site, and to identify the
sources of the bleeding in patients with hemoptysis, but the ideal timing of an endoscopic examination is still unclear.
Methods: We performed a secondary analysis of an observational and multicenter study, aimed at evaluating the
epidemiology of hemoptysis in Italy and the diagnostic yield of the most frequently prescribed examinations. The
aim of the study was to evaluate whether an early bronchoscopy (i.e., performed during active bleeding/≤48 h
after hemoptysis stopped) helps localize bleeding (i.e., site, lobe, lung) and increase diagnostic yield in comparison with
a delayed examination.
Results: Four hundred eighty-six consecutive adult patients (69.2% males; median [IQR] age: 67 [53–76] years) with
hemoptysis requiring an etiological diagnosis and undergoing bronchoscopy were recruited.
Bleeding focus could be located more frequently in case of moderate-severe bleedings than in cases of mild hemoptysis
(site: 70/154, 45.4%, VS. 73/330, 22.1%; p-value < 0.0001; lobe: 95/155, 61.3%, VS. 95/331, 28.7%; p-value < 0.0001; lung:
101/155, 65.1%, VS. 111/331, 33.5%; p-value < 0.0001). Early bronchoscopy showed a higher detection rate of bleeding
source in comparison with delayed examination (site: 76/214, 35.5%, VS. 67/272, 24.6%; p-value = 0.01; lobe: 98/214,
45.8%, VS. 92/272, 33.8%; p-value = 0.007; lung: 110/214, 51.4%, VS. 102/272, 37.5%; p-value = 0.002). Early bronchoscopy
did not provide any advantages in terms of increased diagnostic yield, in the total cohort (113/214, 52.8%, VS. 123/272,
45.2%; p-value = 0.10) and in the severity subtypes (mild: 56/128, 43.8%, VS. 88/203, 43.4%; p-value = 0.94;
moderate-severe: 57/86, 66.2%, VS. 35/69, 50.7%; p-value = 0.051).
Conclusions: Early bronchoscopy helps detect bleeding sources, particularly in cases of moderate-severe
hemoptysis, without increasing diagnostic accuracy.
Trial registration: ClinicalTrials.gov (identifier: NCT02045394).
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Background
Hemoptysis is a challenging symptom associated with
potentially life-threatening medical conditions [1–3]. A
recent European, observational study showed that malig-
nancies were the most frequent etiology [3]. On this
basis, diagnostic work-up should be as comprehensive as
possible [3, 4].
Detection of bleeding sites is key for a successful cli-
nical management, particularly in patients with life-
threatening bleeding [5, 6].
Computed tomography (CT) and bronchoscopy are
accurate techniques for diagnosis and localization of
bleeding sources [1–3, 7, 8]. However, in comparison with
CT, which is more accurate for the diagnosis of vascular
and parenchymal disorders, bronchoscopy could better
assess upper airways and endobronchial abnormalities
(e.g., endobronchial malignancies), as well as it can pro-
vide histopathological and microbiological samples from
central and peripheral lung lesions [3, 9–16]. Furthermore,
it may be useful in patients requiring endobronchial
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interventions, and in case of bilateral lung abnormalities
where radiographic localization of a bleeding source might
be challenging [5, 6].
No guidelines exist on the optimal timing of diagnostic
bronchoscopy in patients with hemoptysis [5]. Only a
few studies assessed whether the timing of endoscopy
may affect the identification and the diagnosis of blee-
ding sources [17, 18]. Their findings were controversial
and, consequently, the ideal timing continues to remain
a matter of debate [5, 17, 18].
The aim of our study was to evaluate whether an early
bronchoscopy (i.e., performed during active bleeding/
≤48 h after hemoptysis stopped) helps detect bleeding
sources and increase diagnostic yield (i.e. ability to pro-
vide histopathological and/or microbiological specimens
useful for an etiological diagnosis) in comparison with a
delayed (i.e., performed after 48 h hemoptysis subsided)
examination [17].
We also investigated whether symptom’s severity might
influence the ability of the endoscopic examination to
localize bleeding focus.
Methods
This was a secondary analysis of an observational and
multicenter study, aimed at evaluating epidemiology of
hemoptysis in Italy and diagnostic yield of the most fre-
quently prescribed diagnostic examinations [3] . The study
protocol was approved by ethical committees of five Ita-
lian participating hospitals (Milan, Mantua, Lodi, Sassari,
Ancona) and registered at ClinicalTrials.gov (identifier:
NCT02045394). Written informed consent was signed by
recruited patients [3].
From July 2013 to September 2015, consecutively re-
cruited adult (i.e., ≥18 years old) patients with hemoptysis
requiring an etiological diagnosis underwent bronchos-
copy. Exclusion criteria were the following: 1) etiology of
hemoptysis already found; 2) refusal to sign the informed
consent [3].
Severity of hemoptysis was assessed by the attending phys-
ician considering the daily amount of expectorated blood:
mild (from some drops of blood to 20ml (ml)/24 h –h-),
moderate (20–500ml/24 h), severe (> 500ml/24 h) [1–3, 6].
Bronchoscopic examination was considered positive
only if it proved an endobronchial bleeding lesion
and/or provided histopathological and/or microbio-
logical specimens, helpful for a definitive etiological
diagnosis [3, 17]. Furthermore, we evaluated the ability
of bronchoscopy to detect the bleeding source (i.e.,
anatomic site, lobe, and lung). The site of the bleeding
was defined as the exact visible hemorrhage source
(e.g., a visible bleeding endobronchial malignancy).
Direct visualization of active bleeding/oozing was con-
sidered suggestive of a bleeding source [17, 19]. Du-
ring the analysis patients undergoing bronchoscopy
were divided into two groups on the basis of the tim-
ing of bronchoscopy in relation with hemoptysis inter-
ruption. The 48-h cut-off was chosen according to the
only available study which evaluated the same topic
(i.e. diagnostic yield and ability of bronchoscopy to
localize the bleeding source in relation to the time of
the intervention) [17].
No pre-defined endoscopic protocols were planned
owing to the lack of evidence-based recommendations
[5, 7]. Decision to perform bronchoscopy, timing of
bronchoscopy, type of bronchoscope (flexible, rigid),
and/or positioning of an endotracheal tube were evalu-
ated by the attending physician case by case after careful
assessment of clinical features, previous individual expe-
riences, and availability of instruments.
Life-threatening hemoptysis was defined as any
hemoptysis where blood loss was > 100 mL in a
time-frame of 24 h, causing abnormal gas exchange/airway
obstruction and/or hemodynamic instability. Notably, daily
blood loss > 100ml (i.e. moderate or severe hemoptysis in
our study) is the smallest amount of blood loss reported in
scientific literature to potentially cause a life-threatening
medical condition [20].
In our study patients with moderate and severe
hemoptysis were combined in a single group. Indeed, as
previously stated, life-threatening hemoptysis might have
occurred only in case of moderate or severe bleeding
(daily blood loss > 100 ml).
Qualitative and quantitative variables were collected
and summarized with absolute and relative (percentages)
frequencies and medians (interquartile ranges, IQR) in
case of non-parametric distribution, respectively. Quali-
tative variables were compared using chi-squared or
Fisher exact test when appropriate. A two-tailed, p-value
less than 0.05 was considered statistically significant.
The statistical software used for the computations was
Stata13.0 (StataCorp, College Station, TX, USA).
Results
A total of 486 adult patients (69.2% males; median [IQR]
age: 67 [53–76] years) with hemoptysis were enrolled.
Hemoptysis volume was self-reported in 416/606
(68.6%) cases, whereas it was estimated by healthcare
professionals in 190/606 (31.4%).
In moderate-severe hemoptysis 87/486 (17.9%) bronchos-
copy was performed within 48 h hemoptysis stopped, while
69/486 (14.2%) after 48 h. In mild hemoptysis 128/486
(26.3%) endoscopic examinations were performed within
48 h, while 202/486 (41.6%) were performed after 48 h.
471/486 (96.9%) bronchoscopies were performed with
a flexible bronchoscope, 2/486 (0.4%) with a flexible
bronchoscope during endotracheal intubation (moderate
bleedings), and 13/486 (2.7%) with a rigid scope. Flexible
bronchoscope was used in 7/12 (58.3%) severe, 134/144
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(93.0%) moderate, and 330/330 (100%) mild bleedings.
Rigid bronchoscopy was performed in 5/12 (41.6%)
severe and 8/144 (5.5%) moderate hemoptysis. In 20/486
(4.1%) patients, hemoptysis was considered potentially
life-threatening. In case of life-threatening hemoptysis
all bronchoscopies were performed as soon as possible
(all during active hemoptysis - within 24 h hemoptysis
subsided).
Bronchoscopy was performed with a diagnostic and
therapeutic (e.g., administration of topical vasoconstric-
tion, Fogarty balloon, argon plasma coagulation, and
laser) aim in 99/486 (20.4%) patients.
Demographic, epidemiologic, clinical, and endoscopic
characteristics of the cohort are shown in Table 1.
Bleeding focus localization occurred more frequently
in case of moderate or severe bleedings in comparison
with mild hemoptysis cases (site: 70/154, 45.4%, VS. 73/
330, 22.1%; p-value < 0.0001; lobe: 95/155, 61.3%, VS.
95/331, 28.7%; p-value < 0.0001; lung: 101/155, 65.1%,
VS. 111/331, 33.5%; p-value < 0.0001).
Early bronchoscopy showed a higher bleeding source
detection rate in comparison with delayed examination
(site: 76/214, 35.5%, VS. 67/272, 24.6%; p-value = 0.01;
lobe: 98/214, 45.8%, VS. 92/272, 33.8%; p-value = 0.007;
lung: 110/214, 51.4%, VS. 102/272, 37.5%; p-value = 0.002)
(Fig. 1). However, no differences were found when bron-
choscopy was performed within 24 VS. within 48 h
(site: 39/116, 33.6%, VS. 37/98, 37.8%; p-value = 0.52;
lobe: 56/116, 48.3%, VS. 42/98, 42.9%; p-value = 0.43;
lung: 63/116, 54.3%, VS. 47/98, 48.0%; p-value = 0.35).
In the subgroup of patients with mild hemoptysis, an
early bronchoscopy did not show a higher ability to
detect the source of the bleeding in comparison with a
delayed one (site: 33/128, 25.8%, VS. 40/202, 19.8%;
p-value = 0.20; lobe: 43/128, 33.6% VS. 52/203, 25.6%;
p-value = 0.12; lung: 51/128, 39.8% VS. 60/203, 29.6%;
p-value = 0.05).
In patients who underwent both CT and bronchoscopy,
CT showed a significantly higher ability to detect the exact
site of bleeding than bronchoscopy, both in early (130/252
(51.6%) VS. 73/190 (38.4%), p-value = 0.006) and delayed
examinations (111/293 (37.9%) VS. 65/261 (24.9%);
p-value = 0.001).
Bronchoscopy showed an overall diagnostic yield of
48.7% (237/487).
The most prevalent definitive clinical diagnosis after
complete work-up where bronchoscopy showed positive
findings (i.e. provided histopathological and/or micro-
biological specimens useful for an etiological diagnosis)
were pulmonary malignancy (97/112, 86.6%;), pneumo-
nia (31/78, 39.7%), bronchiectasis (25/65, 38.5%), and
acute bronchitis (20/65, 30.8%).
In 6/65 (9.2%) patients with a final diagnosis of bron-
chiectasis, the bleeding source was localized only by
bronchoscopy (inconclusive bilateral findings at CT
scan). In 59/65 (90.7%) bronchoscopy was performed to
collect microbiological/cytological samples, showing
positive findings in 25/59 (42.4%) patients.
Early and delayed bronchoscopy did not show relevant
differences in terms of diagnostic yield, for the total co-
hort (113/214, 52.8%, VS. 123/272, 45.2%; p-value: 0.10)
and between severity groups (mild: 56/128, 43.8%, VS.
88/203, 43.4%; p-value: 0.94; moderate-severe: 57/86,
66.2%, VS. 35/69, 50.7; p-value: 0.051) (Fig. 2).
With regard to the main definitive diagnosis, early
bronchoscopy was not associated with a significantly
higher yield (malignancies: 42/45, 93.3%, VS. 55/67,
82.1%, p-value: 0.09; pneumonia: 13/28, 46.4%, VS. 18/50,
36%, p-value: 0.37; bronchiectasis: 15/32, 46.9%, VS. 10/33,
30.3%, p-value: 0.17; acute bronchitis: 13/37, 35.1%,
VS. 7/28, 25%, p-value: 0.38).
Bronchoscopy was performed in 9/11 (81.8%) patients
with hemoptysis who had a final diagnosis of upper
airways bleeding. Notably, it showed pathological
Table 1 Demographic, clinical and bronchoscopic characteristics of the enrolled cohort
Total cohort, n (%) 486 (100)
Age (years), median (IQR) 67 (53–76)
Males, n (%) 336/486 (69.2%)
Hemoptysis severity, n (%) Mild 330/486 (67.9%)
Moderate 144/486 (29.6%)
Severe 12/486 (2.4%)
Life-threatening hemoptysis, n (%) 20/486 (4.1%)
Flexible bronchoscopies, n (%) 471/486 (96.9%)
Flexible bronchoscopies during endotracheal intubation, n (%) 2/486 (0.4%)
Rigid bronchoscopies, n (%) 13/486 (2.7%)
Therapeutic bronchoscopies, n (%) 99/486 (20.4%)
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findings and detected the exact bleeding focus in all
of them (9/9, 100.0%).
Discussion
This secondary analysis, which involves a large cohort of
patients, was conducted to evaluate the diagnostic accu-
racy of bronchoscopy for hemoptysis etiology and for
bleeding source detection in relation with endoscopic
timing. As previously demonstrated by Hirshberg et al.,
our results showed that the bleeding source detection rate
can be higher in case of moderate-severe hemoptysis [1].
This finding is key in case of life-threatening events, when
an accurate localization of the bleeding focus is needed to
administer endoscopic therapies and/or to guide angio-
graphic embolization [5–7].
We also demonstrated that bronchoscopy can better de-
tect bleeding sources (i.e., anatomical site, lobe, and lung)
when it is performed within 48 h from the last hemoptysis
episode. This is significantly relevant for patients with
moderate and severe bleeding. Indeed, when the mild
group is considered alone, we failed to detect any diffe-
rences between early and delayed examinations.
Notably, an investigation performed within 24 h
hemoptysis subsided failed to improve the detection
Fig. 2 Assessment of hemoptysis etiology and timing of endoscopic examination
Fig. 1 Detection rate of the bleeding source (anatomical site, lobe, and lung) in association with the bronchoscopic timing
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rate in the total cohort in comparison with a bron-
choscopy performed within 48 h.
Interestingly, a bronchoscopy performed within 48 h
after hemoptysis interruption does not significantly
increase the diagnostic yield, regardless of symptom
severity and final diagnosis.
Few studies have evaluated the most appropriate timing
for diagnostic bronchoscopy in patients with hemoptysis
[17, 18].
Gong et al. retrospectively analyzed a cohort of 129
patients with hemoptysis and showed that an early
examination (i.e., bleeding subsided less than 48 h prior
to the bronchoscopy) provided a higher bleeding detec-
tion rate; however, diagnostic yield and patient manage-
ment did not improve [17]. Hsiao et al. showed in a
group of non-cancer patients with moderate-severe
hemoptysis that bronchoscopy performed within 24 h
from the first bleeding episode was associated with a
significantly higher detection rate of the bleeding
source [18].
Our findings, based on a larger prospective and multi-
center study, confirmed the results of Gong et al. [17].
In comparison with their findings, we detected a higher
proportion of focal bleeding sites, probably owing to the
higher prevalence of neoplasms (mostly endobronchial)
in our cohort. Moreover, as observed by Gong et al., we
could not detect active bleeding in the majority of the
cases and we could not assess a better endoscopic ability
in localizing bleeding sources associated with a very
early evaluation [17].
Several study limitations should be acknowledged.
The observational nature of the study can increase the
risk of a selection bias; however, the lack of evidence-
based guidelines cannot support the design of an inter-
ventional, randomized control study for ethical reasons.
No guidelines exist on symptom severity [3, 7, 20]. As
previously reported, we grouped patients on the basis
of their daily blood volume loss, without considering
hemodynamic consequences and gas exchange impair-
ment/airway obstruction [1–3, 6]. Life-threatening
hemoptysis may depend on wide volume ranges of
expectorated blood, as well as it may depend on other
clinical variables (i.e., rate of bleeding, airways blood
clearance, extent and severity of any underling lung
and/or cardiac disease) [5, 20].
In case of life-threatening hemoptysis, airways patency
should be immediately preserved; in this context, rigid
bronchoscopy or tracheal intubation are better options
in comparison with flexible bronchoscopy [5, 21]. Fol-
lowing ventilation recovery, flexible instrument may be
used for diagnosis, localization of the bleeding source,
and therapy [5].
We did not evaluate if different endoscopic timing
might affect clinical management. This secondary analysis
was aimed at the ideal timing of diagnostic endoscopy,
without considering its role on long-term outcomes.
We demonstrated that bleeding source detection rate
is higher in case of moderate-severe hemoptysis. It
should be underscored that in critical cases of moderate-
severe hemoptysis (i.e. life-threatening hemoptysis) bron-
choscopy was always performed earlier if compared with
cases of non-critical bleeding. This issue might have
affected the findings of the study.
Notably, the optimal timing of bronchoscopy may
have less clinical relevance nowadays than in the past,
given the availability of highly sensitive imaging tech-
niques. Indeed, as suggested by our findings and by
recent studies, CT imaging and bronchoscopy may have
similar accuracy in the identification of the location of
the bleeding, while CT may show higher sensitivity in
the etiologic diagnosis and is key for bronchial artery
embolization, which remains the cornerstone for the
management of severe hemoptysis cases [7, 22–24].
Conclusions
Bronchoscopy can be crucial for patients with hemoptysis.
An examination performed within 48 hemoptysis stopped
can help detect the bleeding source (particularly in
moderate-severe hemoptysis cases), without increasing its
diagnostic accuracy and regardless of the definitive diag-
nosis. An endoscopic examination performed within 24 h
the symptom subsided does not further improve the de-
tection rate of bleeding sources than a bronchoscopy per-
formed within 48 h.
On the basis of these findings, in case of moderate-se-
vere hemoptysis, if bronchoscopy is deemed crucial or CT
imaging is not available or not useful to detect the bleeding
source, early endoscopy could be recommended. In this
context, an accurate localization of the bleeding focus is
needed to rapidly administer the most adequate therapy.
In case of mild bleeding, a delayed examination may be
considered; the ability of bronchoscopy to diagnose under-
lying diseases and to localize the bleeding source are not
influenced by the timing of the investigation.
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